Video Journal of Oncology (VJOncology)’s Post

Exciting data presented by Dr. Andrew Nixon from Duke Cancer Institute and Dr. Fábio C. P. Navarro from Personalis at #ASCO24! In a study with 33 patients with metastatic esophagogastric cancer (mEGC) treated with pembrolizumab combined with oxaliplatin and capecitabine, NeXT Personal® demonstrated 100% baseline detection. Molecular progression based on ctDNA increases, consistently preceded imaging progression, with a median lead time of 55 days (~2 months). Patients exhibiting an early decrease or clearance in ctDNA levels showed significant improvement in overall survival (OS) (p-value=0.002 and 0.005, respectively) and progression-free survival (PFS) (p-value=0.005 and 0.012, respectively). These results are suggestive that an ultra-sensitive liquid biopsy platform could improve treatment decision-making for patients receiving ICB. Want to learn more about NeXT Personal? Visit us during ASCO at booth 30149. #PrecisionOncology #ctDNA #ImmunoTherapy

“Metabolic pathways may offer personalized therapeutic targets to enhance outcomes for patients with melanoma brain metastases. This project aims to explore how various metabolic pathways influence the development, growth, and response to immune checkpoint blockade in melanoma brain metastasis, utilizing pre-clinical animal models.” This #MRFResearchWednesday, learn more about Afsaneh Amouzegar, M.D., our 2024 Resident Fellow Award recipient from MD Anderson Cancer Center whose research is on "Metabolic Dependencies of Melanoma Brain Metastasis." Read about Afsaneh's work -https://buff.ly/3YMSDkI

For those of you, who have missed Dr. Qiong Gan's webinar: "Unlocking the Potential of Immunostaining in Cytology", the recording is now available online. Dr. Qiong Gan, University of Texas, MD Anderson Cancer Center, Houston TX talks about the special issues related to immunostaining on different cytology specimen preparations, and touches upon controls and validations in cytology. She covers the application of immunostaining in the categorization and typing of tumors, determination of tumor origin etc. In the end, the role of cytology immunostaining in personalized care of cancer patients is discussed, especially breast, lung, and head/neck cancer. 👉🏼 The link to this recorded webinar is in the comments underneath! #InternationalAcademyofCytology #cancerresearch #Cytopathology

Sylvester Comprehensive Cancer Center - How germline testing can guide screening and treatment options Sylvester Comprehensive Cancer Center emphasizes the importance of genetic and genomic testing in cancer treatment. Dr. Carmen Julia Calfa highlights a remarkable 42% reduction in breast cancer mortality over the past 30 years, underscoring how germline testing can significantly guide screening and treatment decisions. https://lnkd.in/eH-Pefgz #BreastCancer #CancerTreatment #OncoDaily #Oncology #Cancer #Health #Medicine

Prostate cancer is a heterogenous disease which poses clinical challenges in terms of both local recurrence and the emergence of metastasis. In this spotlight, Chaxiraxi Arzola explores research by Hirz et al (2023), shedding light on how spatial transcriptomic analysis and single-cell sequencing aid in decoding immune suppression in prostate cancer progression. Learn more today 👉 https://lnkd.in/eMfkSyiX

🚨 Bladder cancer is one of the most common cancers in Canada, and early detection is crucial for better outcomes. A new Genome BC-funded project, led by Dr. Tao Huan (UBC) and Dr. Gang Wang (BC Cancer), is using cutting-edge technology to find biomarkers in urine samples—paving the way for a faster, more affordable test. 🧬💡 This innovation could transform how bladder cancer is diagnosed. 🔗 Learn more about this exciting research on our blog: https://lnkd.in/gX7QDuCz #GenomicsForCancerCare #Biomarkers #CancerResearch #Genomics #Healthinnovation #BladderCancer

On Monday, Dewpoint's Head of Biology Ann Boija, Ph.D., presented the latest data from our colorectal cancer program at The American Association of Cancer Research Congress (AACR). These exciting new data demonstrate how we were able to leverage condensate biology to discover small molecule condensate-modulators (c-mods) that reverse the hyperactive function of beta-catenin by entrapping it into depot condensates to induce profound effects in colorectal cancer PDX animal models.   These results show the huge potential of condensate biology in drugging previously intractable oncology targets and for developing novel treatments for patients suffering from diseases with high unmet need. #AACR24 👉 https://bit.ly/3PSi3bm

August 1st marked #WorldLungCancerDay—a day to raise awareness and highlight the need for more research funding to advance cancer treatment. Research is essential for successful treatments, yet it often falls short due to budget cuts and resource limitations. The complexity of the data and time required to access #RealWorldData make comprehensive studies on prevalent diseases a major challenge. Briya’s mission is to change this, we enable and accelerate medical research, for both #HealthCare providers and #LifeSciences to benefit. Our latest case study offers insights into treating metastatic non-small cell lung cancer. Check it out here: https://lnkd.in/dWBx_A4v

Hats off to the Singapore Gastric Cancer Consortium Duke-NUS Medical School for this compelling analysis: 1,256 gastric samples across 692 subjects from a prospective 10-year study provide a better understanding of gastric cancer progression👉https://bit.ly/3V6rEyK This #Fridayread published in Cancer Cell shows how GeoMx DSP was used to perform spatiotemporal genomic profiling and was key for revealing significant lineage heterogeneity. #spatialprofiling #gastriccancer #tissueheterogeneity

As Bladder Cancer Awareness Month ends, we want to emphasize the ongoing need for education, research, and patient support in the fight against this disease. At Urosphere, we have developed robust preclinical models to support your in vivo and in vitro studies. Thanks to our strong partnership with French institution such as CHU de Toulouse or Clinique Urologique Nantes Atlantis, our biobank of bladder cancer includes human samples, organoids and PDX with specific clinical characteristics : Padcev-resistant, BCG-unresponsive, FGFR-3 mutated, and more. These models are invaluable tools for evaluating new therapeutic approaches. 🤝 Together, we can advance the understanding and treatment of bladder cancer. Let Urosphere be your partner ! More information on https://lnkd.in/dyxJZBmP   #BladderCancerAwareness #CancerResearch #PreclinicalModels #Urosphere #MedicalResearch #PatientSupport